Edwards Lifesciences (EW)
(Delayed Data from NYSE)
$70.27 USD
+1.80 (2.63%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $70.26 -0.01 (-0.01%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$70.27 USD
+1.80 (2.63%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $70.26 -0.01 (-0.01%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth F Momentum F VGM
Zacks News
Edwards Lifesciences (EW) Debuts SAPIEN 3 Ultra RESILIA Valve
by Zacks Equity Research
Edwards Lifesciences' (EW) SAPIEN 3 Ultra RESILIA valve combines its breakthrough RESILIA tissue technology with the SAPIEN 3 Ultra transcatheter aortic heart valve.
Edward Lifesciences (EW) Gains From New Products Amid Cost Woe
by Zacks Equity Research
Edwards Lifesciences (EW) expects full-year 2022 underlying sales to grow on the back of strength in demand for products used in more intense surgeries.
OCPNY or EW: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
OCPNY vs. EW: Which Stock Is the Better Value Option?
Edwards Lifesciences (EW) Gets CE Mark for PASCAL Precision
by Zacks Equity Research
Edwards Lifesciences' (EW) PASCAL Precision system enables precise navigation and implant delivery during mitral and tricuspid regurgitation treatment.
Edwards Lifesciences (EW) Q2 Earnings Meet Estimates, Margins Up
by Zacks Equity Research
Edwards Lifesciences (EW) posts Q2 earnings in line with the Zacks Consensus Estimate, with robust performances across all product groups driving the top line.
Edwards Lifesciences (EW) Matches Q2 Earnings Estimates
by Zacks Equity Research
Edwards Lifesciences (EW) delivered earnings and revenue surprises of 0% and 1.61%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Edwards Lifesciences (EW) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Edwards Lifesciences' (EW) Q2 performance will likely reflect the continued adoption of the RESILIA tissue valves and enhanced sales of the HemoSphere platform.
Edwards Lifesciences (EW) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Edwards Lifesciences (EW) closed at $97.45, marking a -1.99% move from the previous day.
Edwards Lifesciences (EW) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Edwards Lifesciences (EW) closed the most recent trading day at $98.43, moving +0.46% from the previous trading session.
Here's Why You Should Retain Edwards Lifesciences (EW) Now
by Zacks Equity Research
Investors are optimistic about Edwards Lifesciences' (EW) strong segmental performance and the growing demand for its RESILIA tissue valves.
Edwards Lifesciences (EW) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Edwards Lifesciences (EW) closed at $96.03, marking a +1.37% move from the previous day.
OCPNY vs. EW: Which Stock Is the Better Value Option?
by Zacks Equity Research
OCPNY vs. EW: Which Stock Is the Better Value Option?
Edwards Lifesciences (EW) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Edwards Lifesciences (EW) closed the most recent trading day at $90.79, moving +1.62% from the previous trading session.
Edwards Lifesciences (EW) Stock Moves -1.18%: What You Should Know
by Zacks Equity Research
In the latest trading session, Edwards Lifesciences (EW) closed at $87.73, marking a -1.18% move from the previous day.
Edwards Lifesciences (EW) Stock Moves -0.68%: What You Should Know
by Zacks Equity Research
Edwards Lifesciences (EW) closed at $93 in the latest trading session, marking a -0.68% move from the prior day.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
OCPNY vs. EW: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
OCPNY vs. EW: Which Stock Is the Better Value Option?
Top Stock Reports for Eli Lilly, ConocoPhillips & PNC Financial
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), ConocoPhillips (COP), and The PNC Financial Services Group, Inc. (PNC).
Why Is Edwards Lifesciences (EW) Down 11.8% Since Last Earnings Report?
by Zacks Equity Research
Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights Comcast, CME Group, Charter Communications, Airbnb, and Edwards Lifesciences
by Zacks Equity Research
Comcast, CME Group, Charter Communications, Airbnb, and Edwards Lifesciences are part of Top analyst Blog.
Top Analyst Reports for Comcast, CME & Charter Communications
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Comcast Corporation (CMCSA), CME Group Inc. (CME), and Charter Communications, Inc. (CHTR).
Here's Why You Should Hold on to Edwards Lifesciences (EW) Now
by Zacks Equity Research
Investors are optimistic about Edwards Lifesciences (EW) given the strong demand for its RESILIA tissue valves and the PASCAL system.
The Zacks Analyst Blog Highlights T-Mobile US, Deere, PayPal, The PNC Financial Services Group and Edwards Lifesciences
by Zacks Equity Research
T-Mobile US, Deere, PayPal, The PNC Financial Services Group and Edwards Lifesciences have been included in this Analyst Blog.
Top Research Reports for T-Mobile, Deere & PayPal
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including T-Mobile US, Inc. (TMUS), Deere & Company (DE), and PayPal Holdings, Inc. (PYPL).
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.